

Global & USA Biosimilar Market Analysis to 2021



 **KELLY
SCIENTIFIC
PUBLICATIONS**
CUTTING-EDGE MARKET INTELLIGENCE

Global & USA BioSimilar Market Analysis to 2021; BioBetter, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte Colony-Stimulating Factor (G-CSF), Anti-Tumor Necrosis Factor (Anti-TNF), Monoclonal Antibodies (MAbs), Insulins, Interferons, Product Pipelines, Trends, Key Players, Regulations and Strategic Outlook.

TABLE OF CONTENTS

1.0	Introduction	15
1.1	Executive Summary	15
1.2	Objectives of This Report	16
1.3	Key Questions Answered in This Report	17
2.0	Biosimilars: A Brief Overview	19
2.1	Biologic Drugs	19
2.1.1	Development of Biologics	20
2.1.2	Biologics vs. SMDs	20
2.2	Biosimilar Drugs	21
2.2.1	Definition of Biosimilars by The WHO, EMA and FDA	21
2.2.2	Quality Safety and Efficacy (QSE) Assessment of Biosimilars	22
2.2.3	Differences between Biosimilars and Biologics	23
2.2.4	Variations in Development Efforts for Biosimilars, Biologics and Generics	24
2.2.5	Barriers in Developing Identical Copies of Biologics	24
2.2.6	The Cost of Developing Biosimilars	25
2.2.7	Roadmap to a Biosimilar	25
2.2.8	The Emerging Role of Biosimilars	26
2.2.9	Different Names for Biosimilars	27
3.0	Regulations for Biosimilars: An Overview	28
3.1	Biosimilar Drug Registrations in Europe	28
3.1.1	Rules against Automatic Substitution of Biosimilars in E.U. Member States	29
3.1.2	Shareholders' Attitudes towards Biosimilars in Europe	29
3.2	Biosimilar Guidelines in China	30
3.3	Regulatory Pathway for the Approval of Biosimilars in India	31
3.4	Regulatory Pathway for the Approval of Biosimilars in the U.S.	32
3.4.1	U.S. Regulation on Interchangeability of Biosimilars	32
3.4.2	Extrapolation for Biosimilars in the U.S.	33
3.4.3	Totality of Evidence Approach for Biosimilar Approval by FDA	34
3.4.4	Evaluation of Immunogenicity in all Stages of Biosimilar Development	34
3.4.5	Timeline of U.S. Biosimilar Guideline Evolution, 2010-2015	35
3.5	Regulations Regarding the Use of Reference Products by Country	36
3.6	Regulations Regarding Extrapolation by Country	37
3.7	Regulations Regarding Clinical Studies by Country	37
3.8	Regulations Regarding Interchangeability by Country	38
3.9	Regulations Regarding Unique Naming by Country	39
4.0	Development of Biosimilars: An Overview	40
4.1	Unmet Need for Biosimilars	40
4.2	Stages in the Development of Biosimilars	40
4.2.1	Developing a Highly Similar Product	40
4.2.2	Confirming Biosimilarity	41
4.3	Biosimilar Development Stages	41
4.4	Capabilities Required for a Successful Biosimilar Developer	43
4.4.1	Manufacturing Capabilities	43
4.4.2	Clinical Development Experience and Regulatory Know-How	43
4.4.3	Customized Sales and Marketing Skills	43
4.4.4	Long-Term Biosimilar Strategy	43
4.4.5	Upfront Capital Investment	44
4.5	Types of Firms Participating in Biosimilar Development	44
4.6	Key Markets with Biosimilar Approval Pathways	45
4.7	Success Rates in the Development of Biosimilar Drugs	46
4.8	The Most Popular Biosimilar Targets	47

4.8.1	Total Number Biosimilars in Development for the Corresponding Biologics	47
4.8.1.1	Biosimilars in Development for Originator Avastin (Bevacizumab)	48
4.8.1.2	Biosimilars in Development for Originator Enbrel (Etanercept)	49
4.8.1.3	Biosimilars in Phase III Development for Herceptin (Trastuzumab)	49
4.8.1.4	Biosimilars in Development for Humira (Adalimumab)	50
4.8.1.5	Biosimilars in Development for Neulasta (Pegfilgrastim)	51
4.8.1.6	Biosimilars in Development for Rituxan (Rituximab)	52
4.9	Development of MABs	53
4.9.1	Number of Biosimilar MABs in the Pipeline	53
4.9.2	Development of Biosimilar MABs in South Korea	54
4.9.3	Indian Players in Biosimilar Industry	55
4.9.3.1	Indian Biosimilar Pipeline	56
4.10	Biosimilar Map in Table Format	57
5.0	Biobetters: An Overview	60
5.1	Regulatory Considerations for Biobetters	60
5.2	General Differences between a Biosimilar and a Biobetter	61
5.3	Biobetters in Development	61
5.3.1	Development of Biobetters by Stage	62
5.4	Biobetter Development in South Korea	66
6.0	The Approved Biosimilars: An Overview	67
6.1	Authorized Biosimilars in Europe	67
6.1.1	Approved Biosimilars in Europe by Class	69
6.2	An Overview of Nineteen Biosimilars Approved in Europe	70
6.2.1	Abasaglar	70
6.2.2	Abseamed	71
6.2.3	Accofil	71
6.2.4	Bemfola	71
6.2.5	Binocrit	72
6.2.6	Biograstim	72
6.2.7	Epoetin Alfa Hexal	72
6.2.8	Filgrastim Hexal	73
6.2.9	Grastofil	73
6.2.10	Inflectra	73
6.2.11	Nivestim	74
6.2.12	Omnitrope	74
6.2.13	Ovaleap	74
6.2.14	Ratiograstim	74
6.2.15	Remsima	75
6.2.16	Retacrit	75
6.2.17	Silapo	75
6.2.18	Tevagrastim	76
6.2.19	Zarzio	76
6.3	Biosimilar Penetration in Europe	76
6.3.1	Biosimilar EPO Utilization in Europe	82
6.3.1.1	European Market Leaders for Biosimilar EPO	83
6.3.2	Biosimilar G-CSF in Europe	83
6.3.2.1	Penetration of G-CSF Biosimilars in Europe	84
6.3.2.2	The Three Major Biosimilar G-CSF Players in Europe	85
6.4	Price Differentials between Branded Neupogen, Eprex, Genotropin and their Biosimilar Counterparts in Europe	86
6.5	Biosimilars in Germany	88
6.6	Biosimilars Approved and Marketed in Netherlands	89
6.7	Biosimilars Available in U.K. for Myeloma	91
6.8	Biosimilars Approved and Marketed in South Korea	91
6.9	Biosimilars Approved and Marketed in Japan	92
6.10	Biosimilar MABs in Latin America	92
6.11	Biosimilars Approved in India	94
7.0	The Impact of Biosimilars on Originators: An overview	97
7.1	Biosimilar Impact on Epogen	97
7.1.1	Available Biosimilars for Epogen	98

7.1.2	Cost of Epogen Treatment	98
7.2	Impact of Biosimilars on Humira	100
7.2.1	Biosimilars of Humira	100
7.3	Impact of Biosimilars on Remicade	101
7.3.1	Biosimilars for Remicade	102
7.4	Impact of Biosimilars on Neupogen	103
7.4.1	Biosimilars of Neupogen	104
7.5	The Impact of Biosimilars on Neulasta	105
7.5.1	Biosimilars for Neulasta	106
7.6	Impact of Biosimilars on Enbrel	106
7.6.1	Biosimilars to Enbrel	107
7.7	Impact of Biosimilars on Rituxan	108
7.7.1	Biosimilars of Rituxan	108
7.8	Impact of Biosimilars on Herceptin	109
7.8.1	Biosimilars of Herceptin	110
7.9	Impact of Biosimilars on Avastin	111
7.9.1	Biosimilars of Avastin	111
7.10	Impact of Biosimilars on Lantus	112
7.10.1	Biosimilars of Lantus	112
8.0	Top Ten Biologics on the Focus of Biosimilar Developers	114
8.1	Aranesp (Darbepoietin alfa)	114
8.2	Enbrel	115
8.3	Epogen/Procrit/Epex/Erypo	116
8.4	Genotropin	118
8.5	Herceptin	118
8.6	Humira	119
8.7	Neulasta	120
8.8	Neupogen	122
8.9	Remicade	123
8.10	Rituxan	125
9.0	Five Major Classes of Originator Biologics and their Market Performance	127
9.1	Monoclonal Antibodies (MAbs)	127
9.1.1	Biosimilar MAbs in Pipeline	129
9.2	Tumor-Necrosis-Factor Alpha (TNF-alpha)	129
9.2.1	Biosimilar TNF-alpha Blockers	131
9.2.2	Biosimilar TNF-alpha Blockers in Development	132
9.3	Erythropoietin (EPO)	132
9.3.1	Biosimilars of EPO	134
9.4	Insulins	134
9.4.1	FDA-Approved Human Insulins	135
9.4.2	Biosimilar Insulins	137
9.5	Granulocyte-Colony Stimulating Factor (G-CSF)	137
9.5.1	Neupogen's Biosimilars	138
10.0	The Landscape of the Originators of Biosimilars	139
10.1	Domination of Biologics among the Top Ten Drugs in the U.S.	139
10.1.1	Medicare Spending on Biologics	141
10.1.2	U.S. Patent Expiry Dates for Best-Selling Biologics	142
10.2	Top Eight Biologics in European Market	142
10.2.1	Domination of Biologics in Germany	143
10.3	Distribution of Biopharmaceutical Companies	145
10.4	The Most Expensive Drugs	146
10.4.1	The Average Cost of Treatment with Biologic Drugs	147
10.5	Top 15 Biopharma Companies by Revenue	148
10.6	Projected Global Market for Top-Selling Biologics	150
10.7	Projected Sales of Top-Selling Biologics in the U.S. Market	152
10.8	Comparison of Treatment Costs of Biologics and Non-Biologics	154
11.0	A Brief Analysis of Market for Biologics	155
11.1	Global Market for Biologics: Sales and Growth Rate for the Past Six Years	155
11.2	Projected Market for Biologics by Geography	157
11.3	Top Ten Biopharmaceutical Companies	159

11.4	Top-Selling Biologics by Class	160	
11.5	Five Biologics Least Affected by Biosimilars	160	
11.5.1	Sustained Growth for Humira	161	
11.5.2	Lantus Facing Imminent Competition	161	
11.5.3	Higher Growth for Xarelto	162	
11.5.4	Prenvar13: World's leading Vaccine	163	
11.5.5	Eyelea: Surpassing the Predecessors	163	
11.6	Five Biologics Showing Marginal declines in Sales	164	
11.6.1	The Uncertain Revenue Base for Enbrel in the International Market	165	
11.6.2	A Small Decline in Sales for Avastin	165	
11.6.3	Difficult Patient Access to Rituxan	166	
11.6.4	The Lining up of Biosimilars against Herceptin	167	
12.0	Market for Biosimilars: An Overview	168	
12.1	Past Seven Years of Market Performance by Biosimilars	168	
12.2	Loss of Patent Protection for Biologics: The Major Driver of Biosimilars' Market	169	
12.3	Relatively Small Size of Biosimilars' Market Compared to Biologics'	170	
12.4	Favorable Signs for Increased Uptake of Biosimilars	171	
12.5	Recent Events in Biosimilars' Market	171	
12.6	Future of Biosimilars	172	
12.7	Market for Biosimilars by Geography	172	
12.8	Global Market for Biosimilars by Drug Class	174	
12.9	Biosimilar Market Leaders	176	
12.10	Distribution of Biosimilar Companies by Geography	177	
12.10.1	The Largest Markets for Biosimilars in Europe	178	
12.10.1.1	Biosimilars' Market in Germany	179	
12.10.1.2	Norway's Efforts to Achieve Larger Biosimilar Uptake	180	
12.11	The Market Potential for Biosimilars in the U.S.	180	
12.11.1	Optimistic Predictions for the Growth of Biosimilars' Market in the U.S.	181	
12.11.2	Viability of Biosimilars in the U.S.	182	
12.11.3	Projected Savings with Biosimilars in the U.S.	183	
12.11.4	Multiple Challenges for Biosimilars' Entry into the U.S. Market	183	
12.11.5	Break-Even Analysis for Biosimilars in the U.S.	184	
12.11.6	Biosimilars About to Enter the U.S. Market	184	
12.12	SWOT Analysis	186	
12.12.1	Strengths	186	
12.12.2	Weaknesses	186	
12.12.3	Opportunities	186	
12.12.4	Threats	186	
12.12.5	Market Drivers	186	
12.12.6	Barriers	187	
13.0	Selected Company Profiles	188	
13.1	3SBio Inc.	188	
13.1.1	Biosimilars from 3SBio	188	
13.2	Abzena	188	
13.3	Actavis plc	189	
13.3.1	Actavis' Biosimilars	189	
13.4	AET BioTech	189	
13.4.1	Distribution Agreement for Adalimumab	189	
13.4.2	Codevelopment of Adalimumab	189	
13.5	Alvogen Inc.	190	
13.6	Amega Biotech	190	
13.7	Amgen Inc.	191	
13.8	Anhui Anke Biotechnology (Group) Co., Ltd.	192	
13.9	Apotex Inc.	192	
13.9.1	Biosimilars from Apotex	192	
13.10	Avesthagen Ltd.	193	
13.10.1	Agreement with Elpen	193	
13.10.2	Alliance with Kemwell Biopharma	193	
13.11	Baxter International Inc.	193	
13.11.1	Collaboration with Coherus	193	

13.11.2	Collaboration with Momenta	194
13.12	Beijing Four Rings Biopharmaceutical Co., Ltd.	194
13.13	Bharat Biotech International Ltd.	195
13.13.1	Regen-D 150	195
13.13.2	Regen-D 60	195
13.14	Biocon Ltd.	196
13.14.1	Human Insulin	196
13.14.2	Insulin Glargine	196
13.14.3	Insulin Lispro	196
13.14.4	Insulin Aspart	198
13.14.5	Erythropoietin (EPO)	198
13.14.6	Filgrastim (G-CSF)	198
13.14.7	Streptokinase	198
13.14.8	Monoclonal Antibodies (MAbs)	198
13.14.9	Contract Manufacturing	198
13.14.10	Research Services	199
13.15	Biogen Inc.	199
13.15.1	Joint Venture with Samsung	199
13.16	Bionovis SA	200
13.16.1	Bionovis' Product Pipeline	200
13.17	Biopartners GmbH	201
13.17.1	Somatropin	201
13.18	Biosidus S.A.	201
13.19	Bioton Spólka Akcyjna	202
13.19.1	Agreement with Medipolis	202
13.19.2	Agreement with Actavis	202
13.20	Bioviz Technologies Pvt., Ltd.	203
13.21	BioXpress Therapeutics SA	204
13.21.1	Future Programs	204
13.22	Biotechnol AS	205
13.22.1	Tb535	205
13.22.2	Tb434	205
13.23	Boehringer Ingelheim GmbH	205
13.23.1	Boehringer's Biosimilar Efforts	206
13.24	Bolder BioTechnology Inc.	206
13.25	Cadilla Pharmaceuticals Ltd	207
13.25.1	Exemptia	207
13.26	Celltrion Inc.	207
13.26.1	Remsima	207
13.26.2	Product Candidates	208
13.26.2.1	CT-P6	208
13.26.2.2	CT-P10208	
13.27	Cerbios-Pharma S.A	208
13.27.1	Biological Services	208
13.27.2	Biotechnology Services	208
13.27.3	Recombinant Urokinase	209
13.27.4	Recombinant G-CSF	209
13.28	Cipla Ltd.	209
13.28.1	Etaccept	209
13.28.2	Actorise	209
13.29	CJSC Biocad	210
13.29.1	AcellBia	210
13.30	Ckd Bio Corp.	210
13.30.1	Phase I Study of Darbepoietin alfa Biosimilar	210
13.31	Claris Lifesciences Ltd.	211
13.31.1	Fegrast	211
13.32	Coherus Biosciences Inc.	211
13.32.1	The Pipeline	211
13.33	CT Arzneimittel GmbH	212
13.33.1	Biograstim	212

13.34	Dawoong Pharmaceutical Co. Ltd.	212
13.35	Dong-A Socio Holdings Co., Ltd.	212
13.36	Dr. Reddy's Laboratories Ltd.	213
13.36.1	Grafeel	213
13.36.2	Reditux	214
13.36.3	Cresp	214
13.36.4	Peg-Grafeel	214
13.37	Eli Lilly & Co.	214
13.37.1	Abasria	214
13.37.2	Basalgar	215
13.38	Emcure Pharmaceuticals Ltd.	215
13.38.1	Biosimilar for Herceptin	215
13.39	Epirus Biopharmaceuticals Inc.	215
13.39.1	Epirus' Programs	216
13.40	Finox AG	216
13.40.1	Bemfola r-FSH	216
13.41	Fujifilm Diosynth Biotechnologies	217
13.41.1	Joint Venture with Kyowa	217
13.42	Gan & Lee Pharmaceuticals Ltd.	217
13.43	GeneScience Pharmaceuticals Co., Ltd.	218
13.44	Genexine Co. Ltd.	219
13.45	Gennova Biopharmaceuticals Ltd.	219
13.45.1	Gennova's Biosimilar	220
13.46	Genor BioPharma Co., Ltd.	220
13.46.1	Genor's Pipeline	220
13.47	Glenmark Pharmaceuticals Ltd.	221
13.47.1	GBR 830	221
13.47.2	GBR 900	222
13.47.3	GBR 500	222
13.48	Glycotope GmbH	222
13.48.1	Glycotope's Pipeline	222
13.49	Green Cross Corp.	223
13.50	HanAll BioPharma Co., Ltd.	224
13.51	Hanwha Chemical Corp.	224
13.51.1	HD203	224
13.52	Harvest Moon Pharmaceuticals USA Inc.	225
13.52.1	Stable Cell Lines for Biosimilar Development	225
13.53	Hetero Drugs Ltd.	225
13.53.1	Darbepoetin alfa	226
13.54	Hexal AG	226
13.54.1	EPO-alfa Hexal	226
13.54.2	Filgrastim Hexal	226
13.55	Hospira Inc.	227
13.55.1	Retacrit	227
13.55.2	Nivestim	227
13.55.3	Inflectra	227
13.56	Innovent Biologics Inc.	228
13.56.1	IB1301	228
13.56.2	IB1302	228
13.56.3	IB1303	228
13.56.4	IB1305	228
13.56.5	IB1306	228
13.56.6	IB1308	228
13.57	Intas Pharmaceuticals Ltd.	229
13.58	ISU Abxis Co. Ltd.	230
13.58.1	Clotinab	230
13.58.2	ISU101	230
13.58.3	ISU302 & 303	230
13.58.4	ISU201	230
13.59	Kyowa Hakko Kirin Pharma Inc.	231

13.60	LG Life Sciences Co., Ltd.	232
13.60.1	Adalimumab Biosimilar	232
13.61	Lupin Ltd.	232
13.61.1	Lupin's Biosimilar	232
13.62	Mabion SA	233
13.62.1	Phase III for Rituximab Biosimilar	233
13.63	mAbxience S.A.	234
13.63.1	mAbxience's Biosimilars	234
13.64	MacroGenics Inc.	234
13.64.1	Collaboration with Janssen	234
13.64.2	Collaboration with Gilead	234
13.64.3	Collaboration with Boehringer Ingelheim	234
13.64.4	Collaboration with Green Cross	235
13.64.5	Collaboration with Takeda	235
13.64.6	Collaboration with Pfizer	235
13.64.7	MacroGenic's Pipeline	235
13.64.7.1	Margetuximab	235
13.64.7.2	MGA271	235
13.64.7.3	MGD006	235
13.64.7.4	MGD007	236
13.64.7.5	MGD001	236
13.64.7.6	MGD010	236
13.64.7.7	Teplizumab	236
13.65	Medice Arzneimittel Putter GmbH & Co. KG	236
13.65.1	Abseamed	236
13.66	Merck Serono	237
13.66.1	Serono's Biosimilar Programs	237
13.67	Merck & Co., Inc.	238
13.67.1	Biosimilar Development and Commercialization Agreement with Samsung Bioepis	238
13.68	MJ Biopharm Pvt. Ltd.	238
13.69	Mochida Pharmaceutical Co. Ltd.	239
13.69.1	LBEC0101 Trial	239
13.69.2	Collaboration with LG Life Sciences	239
13.70	Momenta Pharmaceuticals Inc.	240
13.70.1	Momenta's Biosimilars Program	240
13.71	Mycenax Biotech Inc.	240
13.71.1	TuNEX241	
13.72	Mylan NV	241
13.72.1	First Trastuzumab Biosimilar	241
13.72.2	Two U.S. Phase III Clinical Trials for Insulin Glargine	241
13.72.3	Partnership with Biocon	242
13.73	Nippon Kayaku Co. Ltd.	242
13.73.1	Nippon's Biosimilars	242
13.74	Oncobiologics Inc.	242
13.75	Pfizer Inc.	243
13.76	Pharma Praxis	244
13.77	PlantForm Corporation	244
13.78	Polpharma SA	245
13.78.1	Polpharma's Collaboration for Biosimilars	245
13.79	Probiomed S.A. de C.V.	245
13.80	Protalix BioTherapeutics Inc.	246
13.80.1	Biobetters from Protalix	246
13.80.1.1	PRX-102	246
13.80.1.2	Oral Anti-TNF	246
13.80.1.3	AIR DNase	246
13.80.1.4	Oral GCD	247
13.81	Ranbaxy Laboratories Ltd. (Sun Pharmaceutical Industries Ltd.)	247
13.81.1	Infimab	247
13.82	Ratiopharm GmbH	247
13.82.1	Ratiograstim	248

13.83	Reliance Life Sciences Pvt. Ltd.	248
13.83.1	ReliFeron	248
13.83.2	ReliPoietin	248
13.83.3	ReliGrast	249
13.83.4	MIRel	249
13.83.5	FostiRel	249
13.83.6	ReliBeta	249
13.83.7	ChorioRel	249
13.83.8	AbcixiRel	249
13.84	Samsung Bioepis Co., Ltd.	250
13.85	Sandoz Inc.	250
13.85.1	Sandoz's Biosimilars	250
13.85.2	Sandoz's Biosimilar Clinical Trials	251
13.86	Shanghai CP Guojian Pharmaceutical Co., Ltd.	251
13.87	Shantha Biotechnics Ltd.	252
13.87.1	Shanpoietin	252
13.89	Stada Arzneimittel AG	253
13.89.1	Biosimilars from Stada	253
13.90	Synthon BV	253
13.90.1	SYD985	254
13.90.2	Antibody Discovery Agreement	254
13.90.3	Global License Agreement for Biosimilar Trastuzumab	254
13.91	Teva Pharmaceutical Industries Ltd.	254
13.91.1	TevaGrastim	254
13.91.2	Ovaleap	254
13.92	USV Ltd.	255
13.92.1	PEG-Filgrastim	255
13.92.2	Teriparatide Injection	255
13.92.3	Somatropin	255
13.92.4	Filgrastim Injection	255
13.93	Wockhardt Ltd.	256
13.93.1	Glaritus	256
13.93.2	Wepox	256
13.94	Xencor Inc.	256
13.95	Xiamen Amoytop Biotech Co., Ltd.	257
13.95.1	Filgrastim (rHuG-CSF)	257
13.95.2	Oprelvekin (rHuIL-11)	258
13.95.3	Molgramostim (rHuGM-CSF)	258
14.0	Biosimilar Market Participants and their Focused Products	259

INDEX OF FIGURES

Figure 2.1: Size Comparison of Small Molecule Drugs (SMD) and Biologics	19
Figure 2.2: Reasons for the Differences in Biologics of the Same Class by Different Manufacturers	24
Figure 2.3: Roadmap to a Biosimilar	25
Figure 3.1: Scientific Justification to Support Extrapolation to Indications not clinically Studied	33
Figure 3.2: Totality of Evidence Approach for Biosimilar Approval by FDA	34
Figure 3.3: Evaluation of Immunogenicity in all Stages of Biosimilar Development	35
Figure 4.1: Development Timeline for Biologics and Biosimilars Compared	41
Figure 4.2: Success Rates in the Development of Biosimilar Drugs	46
Figure 4.3: The Anticipated 2017 Peak in Revenues for Humira and Decline Thereafter	51
Figure 5.1: Number of Biobetters in Development by Stage	63
Figure 5.2: Number of Biobetters in Development by Region/Country	64
Figure 5.3: Companies with the Largest Pipeline of Biosimilars/Biobetters	65
Figure 6.1: Share of HGH, EPO and G-CSF Biosimilars Utilization in European Market	67
Figure 6.2: Approved Biosimilars in Europe by Class	70
Figure 6.3: Biosimilar Penetration in Austria, Belgium and Bulgaria	78
Figure 6.4: Biosimilar Penetration in Croatia, Czech Republic and Denmark	78
Figure 6.5: Biosimilar Penetration in Finland France and Germany	79
Figure 6.6: Biosimilar Penetration in Hungary, Ireland and Italy	79

Figure 6.7: Biosimilar Penetration in Norway, Poland and Portugal	80
Figure 6.8: Biosimilar Penetration in Romania, Slovakia and Slovenia	80
Figure 6.9: Biosimilar Penetration in Spain, Sweden, Switzerland and U.K.	81
Figure 6.10: Top Ten E.U. Countries in Biosimilar Penetration	81
Figure 6.11: The Steady Increase in Biosimilar EPO Utilization in Europe	82
Figure 6.12: The Four European Market Leaders for Biosimilar EPO	83
Figure 6.13: Volume Uptake of Biosimilar G-CSF in Standard Units vs. Daily G-CSF Available Market Products (%) in E.U. Countries	84
Figure 6.14: The Three Major Biosimilar G-CSF Players in Europe	85
Figure 6.15: Price Differential between Branded Neupogen and their Biosimilars in E.U.	87
Figure 6.16: Price Differential between Branded Eprex and Biosimilars in E.U.	87
Figure 6.17: Price Differential between Branded Genotropin and its Biosimilars in France, Germany, Spain and U.K.	88
Figure 7.1: Decline of Sales Revenue for Epogen due to Biosimilars, Through 2020	97
Figure 7.2: Epogen Treatment Cost for Three Major Indications	99
Figure 7.3: Revenue Generated by Epogen for Amgen, 2009-2014	99
Figure 7.4: Marginal Decline of Sales Revenues for Humira, Through 2020	100
Figure 7.5: Humira's Revenue Generation, 2010-2014	101
Figure 7.6: Decline of Sales Revenues for Remicade due to Biosimilars, Through 2020	102
Figure 7.7: Steady and Steep Decline of Revenues for Neupogen, Through 2020	103
Figure 7.8: Impact of Biosimilars on Neulasta's Sales, Through 2020	105
Figure 7.9: Marginal Decline in Sales Revenue for Enbrel due to Biosimilars, Through 2020	107
Figure 7.10: The Estimated Market for Rituxan after Biosimilar Competition, Through 2020	108
Figure 7.11: Impact of Biosimilars on Herceptin, Through 2020	110
Figure 7.12: Impact of Biosimilars on Avastin's Revenues, Through 2020	111
Figure 7.13: Impact of Biosimilars on Lantus, Through 2020	112
Figure 8.1: U.S. Sales Data for Aranesp	115
Figure 8.2: U.S. Sales Data for Enbrel	116
Figure 8.3: U.S. Sales Data for Epogen/Procrit/Eprex/Erypo	117
Figure 8.4: U.S. Sales Data for Herceptin	119
Figure 8.5: U.S. Sales Data for Humira	120
Figure 8.6: U.S. Sales Data for Neulasta	121
Figure 8.7: U.S. Sales Data for Neupogen	123
Figure 8.8: U.S. Sales Data for Remicade	124
Figure 8.9: U.S. Sales Data for Rituxan	126
Figure 9.1: Global Market for Monoclonal Antibodies	127
Figure 9.2: Global Market for TNF-alpha Blockers, Through 2021	131
Figure 9.3: Global Market for Originator Erythropoietin, Through 2021	133
Figure 9.4: Global Market for Human Insulins, Through 2021	135
Figure 10.1: The Growing Share (%) of Biologics, 2014-2023	140
Figure 10.2: Top Biologic Therapy Areas	144
Figure 10.3: Distribution of Biopharmaceutical Companies	146
Figure 10.4: The Daily Cost of Cerezyme, Kadcyla, Humira, Branded Small Molecule Drugs and Generics in the U.S.	146
Figure 10.5: The Average Cost of Treatment with Biologic Drugs in the U.S. and Europe	147
Figure 10.6: Top 15 Biopharma Companies by Revenue	149
Figure 10.7: Global Market for Top-Selling Biologics, 2013-2020	151
Figure 10.8: Projected Sales of Top-Selling Biologics in the U.S. Market	153
Figure 11.1: Steadily-Growing Percent Share (%) of Biologics in Total Pharmaceutical Market	155
Figure 11.2: Global Market for Biologics: Sales and Growth Rate, 2008-2014	156
Figure 11.3: Percent Share of Geographical Markets for Biologics	157
Figure 11.4: Projected Global Markets for Biologics by Geography, Through 2021	158
Figure 11.5: Anticipated Decline for Originator Biologics' Share in the E.U., Through 2021	159
Figure 11.6: Top Ten Biopharmaceutical Companies, 2014	159
Figure 11.7: Top-Selling Biologics by Class	160
Figure 11.8: Global Market for Humira, Through 2021	161
Figure 11.9: Global Market for Lantus, Through 2021	162
Figure 11.10: Global Market for Xarelto, Through 2021	162
Figure 11.11: Global Market for Prenvar13, Through 2021	163
Figure 11.12: Global Market for Eylea, Through 2021	164

Figure 11.13: Global Market for Enbrel, Through 2021	165
Figure 11.14: Global Market for Avastin, Through 2021	166
Figure 11.15: Global Market for Rituxan, Through 2021	166
Figure 11.16: Global Market for Herceptin, Through 2021	167
Figure 12.1: Biosimilar Market Performance, 2007-2014	169
Figure 12.2: Biosimilars' Market Compared with Biologics', Through 2021	170
Figure 12.3: Market for Biosimilars by Geography, Through 2021	173
Figure 12.4: Global Market for Biosimilars by Drug Class, Through 2021	176
Figure 12.5: The Four Biosimilar Market Leaders and their Market Shares, 2008-2014	177
Figure 12.6: Distribution of Biosimilar Companies by Geography	178
Figure 12.7: Leading Biosimilar Markets in Europe, 2007-2013	178
Figure 12.8: Saving Potential of Biosimilars in Germany, Through 2020	179
Figure 12.9: Projected U.S. Biosimilar Market, Through 2020	181
Figure 12.10: Projected Savings with Biosimilars of 11 Specific Biologics in the U.S., 2012-2024	183

INDEX OF TABLES

Table 2.1: Differences between SMDs and Biologics	20
Table 2.2: Comparison between Biosimilars, Biologics and Generics	21
Table 2.3: Methods for QSE Assessment of Biosimilars	22
Table 2.4: Differences between Generics and Biosimilars	23
Table 2.5: Variations in Development Efforts for Biosimilars, Biologics and Generics	24
Table 2.6: E.U. and U.S. Approved Biosimilars and Their Therapeutic Areas	26
Table 2.7: Different Names for Biosimilars	27
Table 3.1: Biosimilar Drug Registration in Europe	28
Table 3.2: Rules against Automatic Substitution of Biosimilars in E.U. Member States	29
Table 3.3: Shareholders' Attitudes towards Biosimilars in E.U.	30
Table 3.4: Biosimilar Guidelines in China	31
Table 3.5: Regulatory Pathway for the Approval of Biosimilars in India	31
Table 3.6: Regulatory Pathway for the Approval of Biosimilars in the U.S.	32
Table 3.7: U.S. Regulation on Interchangeability of Biosimilars	33
Table 4.1: Strengths and Weaknesses of the Four Types of Biosimilar Firms	44
Table 4.2: Key Markets with Biosimilar Approval Pathways	45
Table 4.3: Success Rates in the Development of Biosimilar Drugs	46
Table 4.4: The Most Popular Biosimilar Targets	47
Table 4.5: Total Number Biosimilars in Development for the Corresponding Biologics	48
Table 4.6: Selected Biosimilars in Development for Avastin	48
Table 4.7: Biosimilars in Development for Originator Enbrel (Etanercept)	49
Table 4.8: Biosimilars in Phase III Development for Herceptin (Trastuzumab)	50
Table 4.9: Biosimilars in Development for Humira (Adalimumab)	50
Table 4.10: Biosimilars in Development for Neulasta (Pegfilgrastim)	52
Table 4.11: Biosimilars in Development for Rituxan (Rituximab)	52
Table 4.12: Selected Biosimilar Mabs Developers	53
Table 4.13: Number of Biosimilar MABs in the Pipeline	54
Table 4.14: Development of Biosimilar MABs in South Korea	55
Table 4.15: Indian Players in Biosimilar Industry	56
Table 4.16: Biosimilar Pipelines of Indian Players	57
Table 4.17: Biosimilar Developers from China	57
Table 4.18: Biosimilar Developers from Korea	58
Table 4.19: Biosimilar Developers from Europe	58
Table 4.20: Biosimilar Developers from the U.S.	58
Table 4.21: Biosimilar Developers from India	59
Table 4.22: Biosimilar Developers from South America	59
Table 4.23: Biosimilar Developers from Japan	59
Table 5.1: Differences between the Development of Biosimilars and Biobetters	60
Table 5.2: Selected Biobetters in Development	62
Table 5.3: Number of Biobetters in Development by Stage	63
Table 5.4: Number of Biobetters in Development by Region/Country	64
Table 5.5: Companies with the Largest Pipeline of Biosimilars/Biobetters	65
Table 5.6: Selected Biobetter Development in South Korea	66

Table 6.1: Biosimilars Approved in E.U. as of February 2015	68
Table 6.2: Approved Biosimilars in Europe by Class	70
Table 6.3: Biosimilar Penetration in Europe for HGH, EPO and G-CSF	77
Table 6.4: Approved Biosimilar G-CSF in Europe	84
Table 6.5: Price Differential between Branded Neupogen, Eprex, Genotropin and their Biosimilars	86
Table 6.6: Biosimilars Approved and Marketed in Germany	89
Table 6.7: Biosimilars Approved and Marketed in Netherlands	90
Table 6.8: Biosimilars Available in U.K. for Myeloma	91
Table 6.9: Biosimilars Approved and Marketed in South Korea	91
Table 6.10: Biosimilars Approved and Marketed in Japan	92
Table 6.11: Biosimilar MAbs Marketed in Latin America and others in Development	93
Table 6.12: Biosimilars Approved and Marketed in India as of January 2015	94
Table 7.1: Available Biosimilars for Epogen	98
Table 7.2: Biosimilars of AbbVie's Humira	101
Table 7.3: Biosimilars of Remicade	103
Table 7.4: Biosimilars of Neupogen	104
Table 7.5: Biosimilars of Neulasta	106
Table 7.6: Biosimilars to Enbrel	107
Table 7.7: Biosimilars of Rituxan	109
Table 7.8: Biosimilars of Herceptin	110
Table 7.9: Biosimilars of Avastin	112
Table 7.10: Biosimilars of Lantus	113
Table 8.1: Latest Available U.S. Sales Data for Aranesp	114
Table 8.2: U.S. Sales Data for Enbrel	116
Table 8.3: U.S. Sales Data for Epogen/Procrit/Eprex/Erypo	117
Table 8.4: U.S. Sales Data for Herceptin	118
Table 8.5: U.S. Sales Data for Humira	120
Table 8.6: U.S. Sales Data for Neulasta	121
Table 8.7: U.S. Sales Data for Neupogen	122
Table 8.8: U.S. Sales Data for Remicade	124
Table 8.9: U.S. Sales Data for Rituxan	125
Table 9.1: MAbs Approved and being Reviewed in the U.S. and Europe	128
Table 9.2: Biosimilar MAbs in the Pipeline	129
Table 9.3: Biosimilar TNF-Alpha Blockers Available in Less-Regulated Markets	131
Table 9.4: Biosimilar TNF-alpha Blockers in Development	132
Table 9.5: Biosimilars in Development or Approved	134
Table 9.6: FDA-Approved Human Insulins	136
Table 9.7: The Original G-CSF Products	137
Table 9.8: Biosimilars of Neupogen	138
Table 10.1: Biologics, Among the Top Ten Drugs, 2009-2014	139
Table 10.2: Domination of Biologics among the Top Ten Drugs in the U.S., 2010-2014	141
Table 10.3: Medicare Part B Spending on Biologics	141
Table 10.4: U.S. Patent Expiry Dates for Best-Selling Biologics	142
Table 10.5: Top Eight Biologics among the Top Ten Pharmaceuticals in Europe	143
Table 10.6: Domination of Biologics in Germany, 2009-2014	143
Table 10.7: Top Biologic Therapy Areas	144
Table 10.8: Distribution of Biopharmaceutical Companies	145
Table 10.9: The Average Cost of Treatment with Biologic Drugs in the U.S. and Europe	147
Table 10.10: Top 15 Biopharma Companies by Revenue	148
Table 10.11: Projected Global Market for Top-Selling Biologics, Through 2020	150
Table 10.12: Projected Sales of Top-Selling Biologics in the U.S. Market	152
Table 10.13: Comparison of Treatment Costs of Biologics and Non-Biologics	154
Table 11.1: Global Market for Biologics: Sales and Growth Rate, 2008-2014	156
Table 11.2 Projected Global Markets for Biologics by Geography, Through 2021	158
Table 11.3: Revenue Forecast for Humira, Lantus, Xarelto, Prenvar13 and Eylea, Through 2021	160
Table 11.4: Marginal Decline in Sales for Enbrel, Remicade, Avastin, Rituxan and Herceptin, Through 2021	164
Table 12.1: Biologics Losing Patent Protection, Through 2019	169
Table 12.2: Biosimilars' Market Compared with Biologics', Through 2021	170
Table 12.3: Market for Biosimilars by Geography, Through 2021	173

Table 12.4: Global Market for Biosimilars by Drug Class, Through 2021	175
Table 12.5: The Four Biosimilar Market Leaders and their Market Shares, 2008-2014	177
Table 12.6: Timeline for U.S. Patent Expiration of Branded Biologics	182
Table 12.7: Cost of Developing and Bringing a Biosimilar into the U.S. Market	182
Table 12.8: Break-Even Analysis for Biosimilars in the U.S., Under Three Different Scenarios	184
Table 12.9: Top Five Players Focused on Developing Biosimilars for the U.S. Market	185
Table 13.1: Amgen's Biosimilar Programs in Pivotal Trial (Phase III)	191
Table 13.2: Amgen's Other Biosimilar Products in Development	191
Table 13.3: Biocon's Biosimilar Pipeline	199
Table 13.4: Bionovis' Product Development Partnerships	200
Table 13.5: Binovis' Internal Product Development	200
Table 13.6: BioXpress' Biosimilar Pipeline	204
Table 13.7: Bolder's Product Pipeline	206
Table 13.8: Dong-A's Biomedicine Pipeline	213
Table 13.9: GeneScience's R&D Plan	218
Table 13.10: Genexine's hyFc Pipeline	219
Table 13.11: Genor's Pipeline	221
Table 13.12: Glenmark's Novel Drugs Pipeline	222
Table 13.13: Glycotope's Pipeline	223
Table 13.14: Green Cross' Biopharmaceutical Pipeline	223
Table 13.15: HanAll's Pipeline	224
Table 13.16: Biologics/Biosimilars from Intas Pharmaceuticals	229
Table 13.17: Kyowa's Pipeline	231
Table 13.18: MJ Biopharm's Products and Products in Development	239
Table 13.19: Oncobiologic's Biosimilars Pipeline	243
Table 13.20: Pfizer's Biosimilar Pipeline	243
Table 13.21: Samsung's Biosimilar Pipeline	250
Table 13.22: Sandoz's Biosimilar Pipeline	251
Table 13.23: Xencor's Pipeline	257
Table 14.1: Representative Biosimilar Companies and Product Focus	259
Table 14.1: (Continued)	260
Table 14.1: (Continued)	261

APPENDIX

Appendix 1: Competitive Strategies in Life Sciences: Biobetters vs. Biosimilars	262
Appendix 2: Biosimilar News Updates as of April 2015	267
App. 2.1: Regulatory Framework Updates	267
App. 2.1.1: EMA Issues Finalized Insulin Biosimilars Guideline	267
App. 2.1.2: FDA Announces List of Guidance Documents for 2015	267
App. 2.1.3: Australia Reviewing Plans for Naming Biosimilars	267
App. 2.1.4: Mexico Issues Rules on Biolimbos	267
App. 2.2: Biosimilar Applications Approved and Under Review	268
App. 2.2.1: EMA Accepts Bioepis' Enbrel Biosimilar Candidate SB4 for Regulatory Review	268
App. 2.2.2: Samsung Bioepis Submits Marketing Authorization Application for SB2, a Remicade (Infliximab) Biosimilar Candidate to the EMA	268
App. 2.2.3: FDA Approves First Biosimilar Product Zarxio	268
App. 2.2.4: Hospira Submits Applications to FDA for the Proposed Eopetin alfa Biosimilar	268
App. 2.2.5: FDA Postpones Celltrion's Remicade Biosimilar Review Meeting	268
App. 2.2.5: Apotex Announces FDA has Accepted for Filing its Biosimilar Application for Filgrastim (Grastofil)	269
Appendix 2.3: Company News	269
App. 2.3.1: Pfizer to Acquire Hospira	269
App. 2.3.2: Hospira Launches First Biosimilar MAb Inflectra (Infliximab) in Major European Markets	269
App. 2.3.3: Oncobiologics' ONS-3010 Meets Primary Endpoints	269
App. 2.3.4: Mabion Submits Registration Dossier in Argentina	269
App. 2.3.5: Amgen Announces Positive Results of Phase III Study of Biosimilar Candidate ABP 501	270
App. 2.3.6: Innovent Biologics Inc. Completes Financing Funds to Advance Novel Biologic Pipeline	270

1.0 Introduction

Biosimilars are highly-similar versions of biological drugs that are indicated for cancer, kidney disorders and a wide range of autoimmune diseases. Originator biologics are the most expensive drugs in the pharmaceutical industry and many of them cost nearly \$100,000 per patient per year. These expensive biologics impose a heavy financial burden on patients and healthcare systems, limiting easy access and optimal care. Patent protection for some of the biologics has already expired and many more are to lose patent rights between now and 2020. This has given an opportunity to biotechnology companies to develop and market biosimilars with a cost benefit of about 20% to 30%.

In order to gain a slice of the \$190 billion worth of biologic's market, many biotechnology companies have ventured into the biosimilar sector bringing out less-expensive copies of reference biologics. Biosimilars have been in the E.U. market since 2006 and less-regulated markets such as China, India, and South Korea have a number of biosimilars in their domestic markets. After a long delay, finally, the FDA took a historic decision to approve the first biosimilar Zarxio from Sandoz on March 6, 2015. The coming years will witness the flooding of large number of biosimilars into the U.S., which happens to be the largest market for biopharmaceuticals.

1.1 Executive Summary

The last ten years have witnessed an impressive growth rate for biologic medicines. Nearly 75% of the biopharmaceutical industry research and development (R&D) pipeline includes only biologics. Currently, about 10 of the global top 20 bestselling medicines are biologics and revenues from biological medicines represent 49% of the world's top one hundred drugs in terms of value by 2018. Biologic drugs are quite expensive and the cost per month of treating rheumatoid arthritis with Humira (Adalimumab) can be as high as \$1,800 per month. This cost is over 30 times the cost of the small molecule drug Rheumatrex (Methotrexate).

By espousing competition, biosimilars are expected to bring the advantages of biological drugs to more patients at affordable costs. Nearly, \$600 million per year is spent globally on genuine biosimilars, with the major part of the investment going to manufacturing facilities and trials. As of now, 44 biosimilars have hit the market in different parts of the world and eventually, all biologics will become candidates for biosimilars. Some biopharmaceutical firms are also developing biobetters (biosuperiors). These have the potential to improve on existing medicines and further develop the market, benefiting pharmaceutical companies and patients alike.

For the first time, in 2005, the European Medicines Agency (EMA) created biosimilar guidelines to enable faster approvals than for biologics. As of now, 19 biosimilars have been authorized in Europe for Erythropoietins (EPO), granulocyte-colony stimulating factors (G-CSF); human growth hormone (HGH); follicle inducing hormone; and anti-tumor necrosis factor (anti-TNF) monoclonal antibodies. More biosimilars are anticipated to be launched in the next few years as most of Europe's market leading biologics having an estimated \$81 billion in global annual sales are facing patent expiration.

Herceptin lost its patent protection in 2014, Enbrel will lose its patent in 2015, Lucentis is to lose patent in 2016, Humira's patent will last to 2018 and Avastin will lose its patent in 2019. A competitor drug in development is Amgen's ABP 215, and it is a biosimilar of Roche's monoclonal antibody Avastin (Bevacizumab). Clinical outcome from a comparative evaluation, submitted at the European Society for Medical Oncology congress in September 2014, revealed that ABP 215 which is now in phase III trials is very similar to Avastin in multiple sensitive preclinical pharmacologic evaluations.

Even if biosimilars are cheaper and less risky to develop than reference biologics, the cost involved in developing a biosimilar is about \$100 to \$200 million and takes about eight to ten years. Consequently, biosimilar companies offer products with a small discount of 10% to 35% on the cost of the reference biologic. However, biosimilars are prompting competition and reducing healthcare

costs in Europe. For example, the adoption of biosimilar EPO in Germany between 2007 and 2012 resulted in more than \$550 million in savings.

Sales revenue for biosimilars in the U.S. alone is expected to be \$1.9 billion in 2015 and increase to \$11 billion by 2020. The U.S., Europe and Japan are spending the most on biologics and therefore will become the largest markets for biosimilars. But, the U.S. is yet to have a definitive biosimilar approval pathway. To date, biosimilars represent only 0.5% of the revenues for biologics and they claim 10% of global biologic sales only if there is a strong biosimilar market in the U.S. In August 2014, the FDA accepted the filing of two biosimilars. One is from Sandoz for Neupogen and another from Celltrion for Remicade. It is expected that about five to ten biosimilars will be approved in the U.S. by 2020.

While many companies are involved in the development of biosimilars, some of the companies are actively involved in developing biobetter therapeutics. Biobetters are developed by modifying an existing biologic molecule and incorporating slight differences in the active ingredient. For instance, a MAb can be PEGylated or tagged with a cytotoxic drug to make it better than biosimilars and biologics. Roche's Kadcyra is a biobetter of its own Herceptin. Similarly, TrasGEX is a biobetter of Herceptin, being developed by GlycoTope. Currently, there are 452 biobetters in development compared to 655 biosimilars and 1,241 biologics.

Just like biologics, biobetters also have to meet stringent regulatory requirements. Yet, the cost of development and risks are lower, as the core molecular structures are similar to the originator biologics. They also do not infringe patents and can circumvent biosimilar competition. Companies with successful biologic drugs can bring out biobetters of their own molecules and retain their hold on the market.

1.2 Objectives of This Report

This report provides a comprehensive overview of the size of biosimilars' market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. On total, about 44 biosimilars are available in the global market and currently the E.U. is the major market with 19 approved biosimilars in use. A significant number of biosimilars are available in the markets of China, India, South Korea and Latin America. Biosimilars from these emerging countries are approved by a less-stringent approval pathway and therefore, the commercialization of their products is mostly confined to the domestic markets. The report describes how the long-awaited FDA approval of Zarxio from Sandoz (biosimilar for Amgen's Neupogen) in March 2015 is to transform the otherwise nascent market. The report includes:

- An overview of biosimilars that includes differences between biologics; biosimilars and generics, definition of biosimilars by different agencies, barriers in developing biosimilars, cost of developing biosimilars.
- A summary of regulatory pathways in various geographic regions.
- Development of biosimilars in Europe, China, India, South Korea, Latin America and the sudden spurt in the development of biosimilars in the U.S.
- A list of biosimilar developers in different geographic locations.
- An overview of biobetters that includes regulatory considerations, differences between biosimilars and biobetters, various biobetters that are in developmental stages, and the companies with the largest biobetter pipeline.
- An overview of approved biosimilars in the E.U., U.S., India, South Korea and Latin America.
- The market impact of biosimilars on their reference biologics such as Epogen, Humira, Remicade, Neupogen, Neulasta, Enbrel, Rituxan, Herceptin, Avastin and Lantus through 2021.
- The top ten biologics on the focus of biosimilar developers.

- The five major classes of biologics and their biosimilar counterparts.
- The current landscape of originators of biosimilars.
- Global market for biologics by region, through 2021.
- Global market for biologics by indication, through 2021.
- Global market for biologics by drug class, through 2021.
- Global market for biosimilars by region, through 2021.
- Global market for biosimilars by indication, through 2021.
- Global market for biosimilars by drug class, through 2021.
- Profiles of 95 biosimilar developers, their products in the market and their product pipeline.
- A newsletter in the appendix gives the latest news of biosimilar sector as of February 2015.

1.3 Key Questions Answered in This Report

- How do biologics, biosimilars and generics vary from each other?
- What are the different quality, safety and efficacy assessment tests for biosimilars?
- How much is being spent for developing a biosimilar molecule?
- How many years does a biosimilar take to reach the commercial market?
- How do regulatory pathways differ from region to region?
- What is the need for biosimilars?
- What are the different platforms for the development of biosimilars?
- What is the success rate in the development of a biosimilar when compared to a biologic and generic?
- What are the most attractive target biologics for the development of biosimilars?
- How many biosimilars are being developed for Avastin, Enbrel, Herceptin, Humira, Neulasta, and Rituxan, and what are they?
- How many biosimilar MABs are being developed and what are they?
- How much can the U.S. save by the introduction of biosimilars, through 2024?
- Which companies are involved in developing biosimilar MABs in South Korea?
- Who are the Indian players active in Indian biosimilar industry?
- What are the biosimilar drugs being developed by the Indian biosimilar developers?
- Name the biosimilars approved in the E.U., India, South Korea and Latin America?
- What is the current utilization rate of biosimilars in the E.U. countries?
- The biosimilars approved for use in Germany, Netherlands, U.K., South Korea, Japan, Latin America and India?
- How far the markets of Epogen, Humira, Remicade, Neupogen, Neulasta, Enbrel, Rituxan, Herceptin, Avastin and Lantus will be affected by the entry of biosimilar counterparts?
- What are the top ten biologics that have become the focus of biosimilar developers?
- What are the five major classes of biologics that have attracted the attention of biosimilar developers and what are their current market shares?
- What are the top ten biologic drugs from 2009 to 2014?
- Which biologic drugs dominated the U.S. market, between 2010 and 2014?
- How much is the Medicare Part B spending on biologics in the U.S.?
- What are the top-eight biologic drugs in the E.U. market?
- How many biologics maintain absolute dominance in the German market?
- What is the average cost of a biologic drug in the U.S.?
- How did the market for biosimilars perform between 2007 and 2014?
- How small is the market for biosimilars, when compared to that of biologics?
- What favorable signs are there in the industry to hope for an accelerated growth for biosimilars?
- What is the projected global and regional market for biosimilars from 2014 to 2021?
- What is the projected market for biosimilars by major drug classes from 2014 to 2021?
- Who are the market leaders in the biosimilar sector?

- What was the market for biosimilars in the major E.U. countries between 2007 and 2013?
- How much is the competition between biologics and biosimilars in the German market between 2007 and 2020?
- What is the potential market for biosimilars in the U.S., through 2020?

Global Biosimilar Market

We have seldom seen the emergence of an entirely new pharmaceutical business segment in a short span of time, but it is happening in the drug development industry with biosimilars. Today, there are more than 245 biopharmaceutical, big pharmaceutical and generics companies focusing on developing or already marketing biosimilars.

While the U.S. has approved only one biosimilar therapeutic; Japan, Australia and Europe have approved six, eight and 19 biosimilars respectively. Already, biosimilars have an exemplary safety track record in the E.U., Japan, and Canada where biosimilars are regularly competing against biologics for nearly seven years. The E.U. was the first geographic market to develop the process of authorization of biosimilars, setting an example for many other developing markets to follow suit. As of 2015, the E.U. has approved 19 biosimilars, out of 21 submissions, mostly for three reference biologics such as Somatropin, Epoetin alfa and Filgrastim.

Biosimilars generated revenues of \$1.1 million in 2007, which gradually rose to \$86.9 million in 2014. During this period, the market penetration of biosimilars in Europe and emerging markets was only about 8%. By 2019, KellySciPub forecasts that 50% of the biologics market will belong to off-patent drugs, creating a high market potential for biosimilars.

The top five biologics targeted most by biosimilar developers are Avastin, Enbrel, Herceptin, Humira and Rituxan, which together generate revenues of about \$50 billion annually.

Like most other markets, a competitive biologics market can offer benefits to consumers by lowering prices and enhancing quality. In addition, biosimilars have an unblemished safety track record in the E.U., where biosimilars have been competing against biologics since 2006. Biosimilars have also proved to have a notable impact on drug prices. In the E.U., where biosimilars are already competing with biologics, biosimilars are sold at a 30% discount compared to branded biologic drugs. In spite of the approval of 21 biosimilars in Europe, only 18% of the physicians are aware of these similar versions of biologics. This market analysis report gives cutting-edge information on the following:

- Biosimilar Market Performance, 2007-2014
- Loss of Patent Protection for Biologics: The Major Driver of Biosimilars' Market
- Biologics Losing Patent Protection, Through 2019
- Relatively Small Size of Biosimilars' Market Compared to Biologics'
- Biosimilars' Market Compared with Biologics', Through 2021
- Favorable Signs for Increased Uptake of Biosimilars
- Recent Events in Biosimilars' Market
- Biosimilars Market by Geography (Europe, US, Canada, Russia, Middle-East, Australia, Asia, Africa, South America, China, India), Through 2021
- Biosimilars Global Market by Drug Class (MAbs, TNF-alfa inhibitors, EPO, Insulin, G-CSF, Interferons, HGH), through 2021

- Biosimilar Market Leaders
- The Four Biosimilar Market Leaders and their Market Shares, 2008-2014
- Distribution of Biosimilar Companies by Geography (Europe, North America, Asia/Pacific, Latin America, Middle-East, Africa)
- Leading Biosimilar Markets in Europe (France, Italy, UK, Spain, Germany), through 2020
- Future of Biosimilars

US Biosimilar Market


With the approval of the first biosimilar in the U.S in early 2015 and the expected patent expiration of 12 biologics by 2020, biosimilars are expected to competitively penetrate the US biologic market. Biosimilars have thus become a threat and opportunity for biotechnology and pharmaceutical sectors. Zarxio (Filgrastim, Sandoz) will be launched into the U.S. market in September 2015 and will compete with Neupogen (Amgen) within the US G-CSF market.

Biosimilars will account for 4% to 10% of the biologics market total by 2020, depending on the number of biosimilars launched in the U.S. The U.S. is the largest market for biologics and the biosimilars can achieve 10% of the global sales in 2020, only if the volume growth for biologics is achieved in the U.S. market. According to the Federal Trade Commission, biosimilars can potentially save the U.S. healthcare system, more than \$250 billion through 2022.

The main players looking to penetrate the US biosimilar market are currently Amgen, Mylan, Pfizer, Sandoz and Hospira. This report indicates the following key information on the US biosimilar market:

- The Market Potential for Biosimilars in the U.S.
- Projected U.S. Biosimilar Market, Through 2020
- Optimistic Predictions for the Growth of Biosimilars' Market in the U.S.
- Timeline for U.S. Patent Expiration of Branded Biologics
- Viability of Biosimilars in the U.S.
- Cost of Developing and Bringing a Biosimilar into the U.S. Market
- Projected Savings with Biosimilars in the U.S.
- Projected Savings with Biosimilars of 11 Specific Biologics in the U.S., 2012-2024
- Multiple Challenges for Biosimilars' Entry into the U.S. Market
- Break-Even Analysis for Biosimilars in the U.S.
- Biosimilars About to Enter the U.S. Market
- Top Five Players Focused on Developing Biosimilars for the U.S. Market

Figure S1: Biosimilar Market Performance, 2007-2014



KellyScipub